BRAF and neoplasm: Cohort A (BRAF V600E or V600K mutation-positive): Dabrafenib/Trametinib/MEDI4736.Cohort B (BRAF mutation-negative) Trametinib/MEDI4736.Cohort C (BRAF mutation-negative): Trametinib/MEDI4736. Study evaluation will include maximum tolerated dose, safety, anti-tumor activity, pharmacokinetic, and immunogenicity of MEDI4736.